Fundraising FoxFACIT (Fight Against Cancer Innovation Trust) — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence.
BiotechHealthtechToronto
Juan Carlos Zuniga-Pflucker(Executive Officer, Director)
BoardFei Shen(Director)Ferdinand Massari(Director)
Co-investorsEisai Innovation, Inc.Boehringer Ingelheim Venture Fund
Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
BiotechMedical Devices
Arthur Fratamico(Executive Officer, Promoter)Deborah Geraghty, Ph.D.(President and Chief Executive Officer)
Co-investorsToronto Innovation Acceleration PartnersAmplitude Venture CapitalBill & Melinda Gates Foundation
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Notch Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.